Mounjaro vs Ozempic: Key Differences Explained
Mounjaro and Ozempic are both injectable prescription medications approved for type 2 diabetes, but they work differently and appear on many weight-loss clinic websites. This page focuses on FDA-approved facts and named trial evidence rather than marketing language.
Quick comparison table
| Category | Mounjaro | Ozempic |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA approval date | May 2022 | 2017 |
| Approved indication | Type 2 diabetes only, not FDA-approved for weight loss, per FDA prescribing information. | Type 2 diabetes only, not FDA-approved for weight loss, per FDA prescribing information. |
| Mechanism | Dual GIP/GLP-1 receptor agonist per FDA prescribing information. | GLP-1 receptor agonist per FDA prescribing information. |
| Dosing frequency | Once weekly injection; same tirzepatide escalation schedule used for Zepbound per FDA prescribing information. | Once weekly injection; starts at 0.25 mg and escalates to 0.5 mg, with up to 2 mg weekly per FDA prescribing information. |
| Average weight loss | SURPASS-2 trial showed tirzepatide produced greater weight loss than semaglutide 1 mg in adults with type 2 diabetes. | The reference file cites semaglutide weight-loss results from Wegovy trials, and notes Ozempic itself is not FDA-approved for weight loss. |
| Common side effects | Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia per tirzepatide labeling. | Nausea, diarrhea, vomiting, constipation, abdominal pain per semaglutide labeling. |
| Approximate monthly cost range | About $1,000-1,100/month; prices vary by pharmacy and location as of early 2025. | About $900-1,000/month; prices vary by pharmacy and location as of early 2025. |
Drug facts on this page are summarized from FDA prescribing information and named clinical trials listed in the source notes below.
What is Mounjaro?
Mounjaro is Eli Lilly's brand name for tirzepatide, a dual GIP/GLP-1 receptor agonist, per FDA prescribing information. The FDA approved Mounjaro in May 2022 for type 2 diabetes. It is often mentioned in weight-loss discussions because tirzepatide has produced substantial average weight-loss results in clinical trials, but the Mounjaro label itself is for diabetes, not chronic weight management.
One of the most important named comparisons is the SURPASS-2 trial, which compared tirzepatide with semaglutide 1 mg in adults with type 2 diabetes. The reference file states tirzepatide showed superior A1C reduction and weight loss versus semaglutide 1 mg. That is useful context, but it does not answer every consumer question because it did not compare tirzepatide with Wegovy's 2.4 mg semaglutide dose used for chronic weight management.
Per FDA prescribing information, Mounjaro is a once-weekly injection with dose escalation over time. Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, and dyspepsia. The label also includes the thyroid C-cell tumor boxed warning observed in rodents and warnings about pancreatitis, gallbladder issues, and hypoglycemia when used with insulin.
What is Ozempic?
Ozempic is Novo Nordisk's semaglutide product approved for type 2 diabetes, per FDA prescribing information. It is also a once-weekly injection, but unlike tirzepatide it acts only as a GLP-1 receptor agonist. Ozempic is widely recognized outside diabetes care because semaglutide is also the active ingredient in Wegovy, the higher-dose weight-management brand.
The reference file makes an important legal and clinical distinction: Ozempic is not FDA-approved for weight loss. When people talk about semaglutide trial results such as STEP 1, they are usually referring to Wegovy, not Ozempic. STEP 1 reported average 14.9% body weight loss over 68 weeks, but that should be cited accurately and not casually reassigned to the Ozempic label.
Per FDA prescribing information, Ozempic dosing begins at 0.25 mg weekly, then moves to 0.5 mg and can go up to 2 mg weekly. Its common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Like semaglutide more broadly, Ozempic also carries the thyroid C-cell tumor boxed warning observed in rodents and requires a clinician-guided risk discussion.
Key Differences
- Mounjaro contains tirzepatide and activates GIP plus GLP-1 receptors; Ozempic contains semaglutide and activates GLP-1 receptors only, per FDA prescribing information.
- Both are FDA-approved for type 2 diabetes, not weight loss, per FDA prescribing information.
- SURPASS-2 compared tirzepatide with semaglutide 1 mg and found greater weight loss with tirzepatide in that diabetes trial.
- Ozempic pricing is often slightly lower than Mounjaro retail pricing as of early 2025, though actual costs vary widely.
- Consumers often confuse Ozempic with Wegovy and Mounjaro with Zepbound, but those are different labels with different approved indications.
Which One Is Right for You?
This is not a recommendation. The better question is which factors you should discuss with your doctor before choosing a medication. Consult your healthcare provider about:
- Whether your treatment goal is diabetes management, weight management, or both, and which FDA-approved indication fits your situation.
- How trial evidence like SURPASS-2 should be interpreted for your health history.
- What your insurance covers for Mounjaro versus Ozempic.
- Whether side-effect profile, dosing, and prior response to GLP-1 medications affect the decision.
- Whether a weight-management product such as Zepbound or Wegovy is more appropriate to discuss than a diabetes-labeled product.
Side Effects Comparison
| Side effect or warning | Mounjaro | Ozempic |
|---|---|---|
| Nausea | 31% on tirzepatide label context | Semaglutide label reports nausea among common side effects |
| Diarrhea | 23% | Common on semaglutide label |
| Vomiting | 14% | Common on semaglutide label |
| Constipation | 13% | Common on semaglutide label |
| Decreased appetite | 22% | Not listed among top semaglutide figures in reference |
| Boxed warning | Thyroid C-cell tumor warning in rodents | Thyroid C-cell tumor warning in rodents |
Side-effect summaries are based on FDA prescribing information. Individual experiences vary. Consult your healthcare provider.
Cost Comparison
Mounjaro is approximately $1,000-1,100 per month without insurance as of early 2025.
Ozempic is approximately $900-1,000 per month without insurance as of early 2025.
Prices vary by pharmacy and location, and insurance coverage may matter more than retail list price.
Ask your healthcare provider and pharmacy whether a diabetes indication or a weight-management indication changes coverage options.
Pricing is approximate and based on the reference file as of early 2025. Prices vary by pharmacy and location. Consult your healthcare provider and pharmacy for current pricing.
Frequently Asked Questions
Is Mounjaro approved for weight loss?
No. Mounjaro is FDA-approved for type 2 diabetes, not weight loss, per FDA prescribing information.
Is Ozempic approved for weight loss?
No. Ozempic is FDA-approved for type 2 diabetes, not weight loss, per FDA prescribing information.
What trial compared Mounjaro and Ozempic?
The reference file cites SURPASS-2, which compared tirzepatide with semaglutide 1 mg in adults with type 2 diabetes.
Are both drugs weekly injections?
Yes. Both Mounjaro and Ozempic are once-weekly injections per FDA prescribing information.
Should I compare Mounjaro to Ozempic or Zepbound to Wegovy?
That depends on the question. Mounjaro and Ozempic are diabetes-labeled products, while Zepbound and Wegovy are the brands approved for chronic weight management.
Find Clinics
Browse GLP-1 clinics, compare treatment options, and bring these questions to a licensed medical professional. Consult your healthcare provider before starting any medication.
Find clinics discussing tirzepatide and semaglutide optionsData sources
- Mounjaro prescribing information (FDA)
- Ozempic prescribing information (FDA)
- SURPASS-2 trial
- Wegovy prescribing information (FDA) for semaglutide trial context
Drug information sourced from FDA-approved prescribing labels and published clinical trial data. Pricing information is approximate and may not reflect current costs. Last updated March 2026.
This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting any medication. Individual results may vary. Consult your healthcare provider.